Guba Susan C相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

一项针对实体瘤和非小细胞肺癌的 galunisertib 联合 nivolumab 的 Ib/II 期研究

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-023-11153-1

Nadal, Ernest; Saleh, Mansoor; Aix, Santiago Ponce; Ochoa-de-Olza, Maria; Patel, Sandip Pravin; Antonia, Scott; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Estrem, Shawn T; Liu, Jiangang; Avsar, Emin; Lin, Wen Hong; Benhadji, Karim A; Gandhi, Leena; Guba, Susan C; Diaz, Inmaculada Ales

细胞生物学

发表日期：2023

文献求助收藏

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

恩扎卢胺联合沙莫托利西布（LY3023414）或安慰剂治疗转移性去势抵抗性前列腺癌患者的Ib/II期研究

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-21-2326

Sweeney, Christopher J; Percent, Ivor J; Babu, Sunil; Cultrera, Jennifer L; Mehlhaff, Bryan A; Goodman, Oscar B; Morris, David S; Schnadig, Ian D; Albany, Costantine; Shore, Neal D; Sieber, Paul R; Guba, Susan C; Zhang, Wei; Wacheck, Volker; Donoho, Gregory P; Szpurka, Anna M; Callies, Sophie; Lin, Boris Kin; Bendell, Johanna C

发表日期：2022

文献求助收藏

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

TGFβ受体I激酶抑制剂galunisertib联合抗PD-L1抗体durvalumab治疗转移性胰腺癌的安全性和活性

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2020-002068

Melisi, Davide; Oh, Do-Youn; Hollebecque, Antoine; Calvo, Emiliano; Varghese, Anna; Borazanci, Erkut; Macarulla, Teresa; Merz, Valeria; Zecchetto, Camilla; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Gandhi, Leena; Estrem, Shawn T; Benhadji, Karim A; Lanasa, Mark C; Avsar, Emin; Guba, Susan C; Garcia-Carbonero, Rocio

发表日期：2021

文献求助收藏

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

一项针对新诊断恶性胶质瘤患者的 1b/2a 期研究，评估了转化生长因子-β受体I小分子抑制剂 galunisertib 与基于替莫唑胺的标准放化疗方案联合治疗的疗效。

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-020-00910-9

Wick, Antje; Desjardins, Annick; Suarez, Cristina; Forsyth, Peter; Gueorguieva, Ivelina; Burkholder, Tiana; Cleverly, Ann Louise; Estrem, Shawn T; Wang, Shuaicheng; Lahn, Michael M; Guba, Susan C; Capper, David; Rodon, Jordi

发表日期：2020

文献求助收藏

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

一项 II 期随机研究，比较了加鲁尼塞替单药治疗或加鲁尼塞替联合洛莫司汀治疗与洛莫司汀单药治疗在复发性胶质母细胞瘤患者中的疗效。

期刊:Neuro-Oncology

影响因子:13.4

doi:10.1093/neuonc/now009

Brandes, Alba A; Carpentier, Antoine F; Kesari, Santosh; Sepulveda-Sanchez, Juan M; Wheeler, Helen R; Chinot, Olivier; Cher, Lawrence; Steinbach, Joachim P; Capper, David; Specenier, Pol; Rodon, Jordi; Cleverly, Ann; Smith, Claire; Gueorguieva, Ivelina; Miles, Colin; Guba, Susan C; Desaiah, Durisala; Lahn, Michael M; Wick, Wolfgang

细胞生物学

发表日期：2016

文献求助收藏

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer

PRONOUNCE：一项随机、开放标签的III期研究，比较一线培美曲塞+卡铂治疗后序贯培美曲塞维持治疗与紫杉醇+卡铂+贝伐单抗治疗后序贯贝伐单抗维持治疗在晚期非鳞状非小细胞肺癌患者中的疗效。

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1097/JTO.0000000000000366

Zinner, Ralph G; Obasaju, Coleman K; Spigel, David R; Weaver, Robert W; Beck, J Thaddeus; Waterhouse, David M; Modiano, Manuel R; Hrinczenko, Borys; Nikolinakos, Petros G; Liu, Jingyi; Koustenis, Andrew G; Winfree, Katherine B; Melemed, Symantha A; Guba, Susan C; Ortuzar, Waldo I; Desaiah, Durisala; Treat, Joseph A; Govindan, Ramaswamy; Ross, Helen J

细胞生物学

发表日期：2015

文献求助收藏

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

galunisertib（LY2157299 一水合物）是一种转化生长因子-β信号通路的小分子抑制剂，目前正在进行临床开发

期刊:Drug Design Development and Therapy

影响因子:5.1

doi:10.2147/DDDT.S86621

Herbertz Stephan, Sawyer J Scott, Stauber Anja J, Gueorguieva Ivelina, Driscoll Kyla E, Estrem Shawn T, Cleverly Ann L, Desaiah Durisala, Guba Susan C, Benhadji Karim A, Slapak Christopher A, Lahn Michael M

发表日期：2015

文献求助收藏

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer

PointBreak：一项随机III期研究，比较培美曲塞联合卡铂和贝伐单抗治疗后序贯培美曲塞和贝伐单抗维持治疗与紫杉醇联合卡铂和贝伐单抗治疗后序贯贝伐单抗维持治疗在IIIB期或IV期非鳞状非小细胞肺癌患者中的疗效。

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2012.47.9626

Patel, Jyoti D; Socinski, Mark A; Garon, Edward B; Reynolds, Craig H; Spigel, David R; Olsen, Mark R; Hermann, Robert C; Jotte, Robert M; Beck, Thaddeus; Richards, Donald A; Guba, Susan C; Liu, Jingyi; Frimodt-Moller, Bente; John, William J; Obasaju, Coleman K; Pennella, Eduardo J; Bonomi, Philip; Govindan, Ramaswamy

细胞生物学

发表日期：2013

文献求助收藏